The European Commission is making a Requests for submissions (RfS) to submit the “Critical Medicines Act,” an EU piece designed to address severe shortages of essential medicines, particularly antibiotics, insulin, and painkillers. The deadline for this process has been set at 11 March, and the pharma industry, led by the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), has called for a delayed response. This extends beyond their initial offer of January 1, 2024, to a 100-day period.
The EUCOPE is concerned that the process, while intended to ensure timely regulation, may have ignored a more thorough evaluation. This is reflected in their follow-up call for stakeholder feedback, which, according to letters from CFPA and HMRC, was activated on December 25. However, no immediate progress has been made, highlighting the criticism they face from pharmaceutical companies.
The EU’s pharma industry expresses strong opposition to such delays. TheRefs Commissioner, Oliver Várhelyi, has repeatedly emphasized the importance of addressing the EU’s critically sourced medicines. The pharma world, particularly the German drug giant Bayer, which is part of the Critical Medicines Alliance, has toda formal and emotional investment in these negotiations. Bayer has detailed concerns regarding the omission of the impact assessment process in their RfS, marking a potential gap in the analysis. This issue includes the possibility of environmental and social impacts, job losses, and economic inefficiencies.
Another key issue involves the lack of an impact assessment method in the analyzing body. In 2022, the European Commission introduced the Better Regulation principles for the Health Experience (RHX) phase, but the department skipped the findings from pilot studies and the strategic review. This omission is significant, as it may mislead regulatory bodies about the long-term effects of the Critical Medicines Act.
The six industry leaders—Bayer, Roche, EUCOPE, EFCOPE, EFPIA, and Takeda—have appeared against the movement, with Bayer emphasizing the necessity of an impactful assessment to inform policy. The concerns are not solely on the potential short-term benefits but include a broader emphasis on better oversight.
The broader picture suggests a complex relationship that could be politically volatile. The European parliament is considering molecular biology collaborations, ifronented by the Health Commissioner, with the aim of accelerating the act’s progress. This may further escalate tensions among the sectors and policymakers.
In the end, the delta xp is on the horizon, raising significant questions about the health and economic well-being of millions, who are at the center of the EU’s executive order. These concerns extend beyond the finer details of the act. As the process continues, potential impacts on drug development, job losses, and the overall effectiveness of the proposal will emerge as a critical issue for years to come.
